DK1634949T3 - Fremgangsmåde til at generere aktiverede T-celler og antigen-inkuberede antigen-præsenterende celler - Google Patents

Fremgangsmåde til at generere aktiverede T-celler og antigen-inkuberede antigen-præsenterende celler

Info

Publication number
DK1634949T3
DK1634949T3 DK05076809.2T DK05076809T DK1634949T3 DK 1634949 T3 DK1634949 T3 DK 1634949T3 DK 05076809 T DK05076809 T DK 05076809T DK 1634949 T3 DK1634949 T3 DK 1634949T3
Authority
DK
Denmark
Prior art keywords
antigen
cells
activated
pbls
loaded
Prior art date
Application number
DK05076809.2T
Other languages
English (en)
Inventor
Babita Agrawal
Mark J Krantz
Mark A Reddish
Michael B Longenecker
Original Assignee
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc
Application granted granted Critical
Publication of DK1634949T3 publication Critical patent/DK1634949T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK05076809.2T 1997-05-08 1998-05-07 Fremgangsmåde til at generere aktiverede T-celler og antigen-inkuberede antigen-præsenterende celler DK1634949T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4594997P 1997-05-08 1997-05-08
EP98921011A EP0986636B1 (en) 1997-05-08 1998-05-07 Method for generating activated t-cells and antigen-pulsed antigen-presenting cells

Publications (1)

Publication Number Publication Date
DK1634949T3 true DK1634949T3 (da) 2011-03-28

Family

ID=21940709

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05076809.2T DK1634949T3 (da) 1997-05-08 1998-05-07 Fremgangsmåde til at generere aktiverede T-celler og antigen-inkuberede antigen-præsenterende celler

Country Status (10)

Country Link
US (1) US6600012B1 (da)
EP (3) EP1634949B1 (da)
JP (1) JP4480800B2 (da)
AT (2) ATE394474T1 (da)
AU (1) AU727863B2 (da)
CA (1) CA2289742C (da)
DE (2) DE69842060D1 (da)
DK (1) DK1634949T3 (da)
ES (1) ES2357960T3 (da)
WO (1) WO1998050527A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906744A1 (de) * 1999-02-18 2000-08-24 Martin Roecken Verfahren zur Herstellung antitumoraler Th1-Zellen
CA2368967A1 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
CA2383737C (en) * 1999-09-08 2011-01-18 Transgene S.A. Muc-1 derived peptides
GB9921337D0 (en) * 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
JP2004533421A (ja) * 2001-03-27 2004-11-04 バイオミラ，インコーポレイテッド Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
US7282222B2 (en) 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
ES2375992T3 (es) * 2002-04-15 2012-03-08 Oncothyreon Inc. Glucolipopéptidos sintéticos como vacunas.
WO2004022590A2 (en) * 2002-09-05 2004-03-18 Cell Center Cologne Gmbh Immunogenic muc1 glycopeptides
BR0314471A (pt) * 2002-10-10 2005-08-02 Us Dept Veterans Affairs Detecção, localização e estadiamento de tumores usando linfócitos ativados classificados dirigidos a um epitopo especìfico do tumor
US20050045205A1 (en) * 2003-08-29 2005-03-03 Stach Steven R. Apparatus and method for cleaning printed circuit boards
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
EP1697399B1 (en) * 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
TWI395591B (zh) 2004-04-01 2013-05-11 Oncothyreon Inc 黏液性糖蛋白（ｍｕｃ-１）疫苗
WO2006050116A1 (en) * 2004-11-02 2006-05-11 Biomedical Research Models, Inc. Methods of cancer treatment/prevention using cancer cell-specific surface antigens
US8871250B2 (en) 2005-06-28 2014-10-28 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
RU2377994C1 (ru) * 2008-05-21 2010-01-10 Леонид Валентинович Загребин Способ иммунореабилитации онкозаболеваний
US20100059084A1 (en) * 2008-09-10 2010-03-11 Austin American Technology Corporation Cleaning and testing ionic cleanliness of electronic assemblies
BR112012028893A2 (pt) 2010-05-10 2017-12-12 Ascend Biopharmaceuticals Pty Ltd composições imunoestimuladoras e de vacina
EP2678005A4 (en) 2011-02-24 2015-06-10 Oncothyreon Inc GLUCOLOPOPEPTIDE MUC1-BASED VACCINE WITH AN ADJUVANS
EP2800762B1 (en) 2012-01-03 2018-01-03 The United States of America, as represented by the Secretary, Department of Health and Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
WO2014183823A1 (en) 2013-05-14 2014-11-20 Merck Patent Gmbh Method of treating lung cancer by vaccination with muc-1 lipopeptide
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0765381B1 (en) 1994-06-13 1999-08-11 Unilever N.V. Bleach activation
PT765386E (pt) * 1994-06-14 2015-02-06 Univ Leland Stanford Junior Processos para a activação in vivo de células t, através de células dendríticas pulsadas com antigénio
AU5849796A (en) * 1994-12-27 1996-08-07 United Biomedical Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
AU6330896A (en) * 1995-06-07 1996-12-30 Governors Of The University Of Alberta, The A method for eliciting a th1-specific immune response
CA2282300C (en) 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen

Also Published As

Publication number Publication date
AU7371298A (en) 1998-11-27
EP0986636B1 (en) 2008-05-07
ATE394474T1 (de) 2008-05-15
CA2289742A1 (en) 1998-11-12
JP2001525668A (ja) 2001-12-11
DE69839443D1 (de) 2008-06-19
CA2289742C (en) 2013-07-16
DE69842060D1 (de) 2011-01-27
EP0986636A1 (en) 2000-03-22
EP2341072A3 (en) 2013-10-30
ES2357960T3 (es) 2011-05-04
EP2341072A2 (en) 2011-07-06
EP1634949B1 (en) 2010-12-15
JP4480800B2 (ja) 2010-06-16
ATE491465T1 (de) 2011-01-15
EP1634949A1 (en) 2006-03-15
US6600012B1 (en) 2003-07-29
WO1998050527A1 (en) 1998-11-12
AU727863B2 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
DK1634949T3 (da) Fremgangsmåde til at generere aktiverede T-celler og antigen-inkuberede antigen-præsenterende celler
DE3650184D1 (de) Zellenfreier t-zellenantigenrezeptor und klinische verwendung.
EP0957161A4 (en) METHOD FOR ACTIVATING HUMAN, ANTIGEN-ACTIVATING CELLS, ACTIVATED HUMAN, ANTIGEN-ACTIVATING CELLS, AND APPLICATIONS THEREOF
ES2190432T3 (es) Activacion in vitro de celulas t citotoxicas.
ES2059537T3 (es) Metodo para purgar in vitro celulas tumorales residuales con la ayuda de celulas citotoxicas activadas por una linfocina.
AR004545A1 (es) Derivados de purin-6-ona, procedimientos para su preparacion, el uso de los mismos en la preparacion de medicamentos, medicamentos que los contieneny un procedimiento para preparar dichos medicamentos
ES2177964T3 (es) Procedimiento de produccion de celulas t activadas marcadas especificas de tumores y su uso para el tratamiento de tumores.
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
DE69512219D1 (de) Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
DE69830663D1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
GR880100198A (el) Τμήματα DNA, πολυπεπτίδια και αντισώματα σχετιζόμενα προς τον παράγοντα ιστών του αν?ρώπου.
PT765386E (pt) Processos para a activação in vivo de células t, através de células dendríticas pulsadas com antigénio
ES2033981T3 (es) Procedimiento para la preparacion de proteinas bifuncionales.
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
NO965395D0 (no) Humane, monoklonale antistoffer som er spesifikke mot cellecyklus-uavhengig gliom-overflateantigen
ES2177509T3 (es) Empleo de anticuerpos para la vacunacion contra el cancer.
ATE321843T1 (de) Zellen, kulturverfahren, und ihre verwendung in autologer transplantationstherapie
DK0843731T3 (da) Adenovirusvektorer til genterapi
Slovin et al. Immunological approaches for the treatment of prostate cancer
NO983375L (no) Retroviral vektor og anvendelse derav i genterapi
GB9123036D0 (en) Cell growth indicators
ES2132027A1 (es) Desarrollo de una piel artificial mediante cultivo de queratinocitos sobre una base de fibrina y fibroblastos humanos y metodo de preparacion de esta piel para trasplante.
ATE359372T1 (de) Vektoren zur inhibierung von viralem und tumorwachstum
WO2000015767A3 (en) Antigen-presenting cells and their use in therapy